---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061998"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:44:03.363971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life

## Summary
- Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).
- Phase 1 healthy volunteer data showed half-life of ~75 days and potentially best-in-class PK profile.
- 16-week proof-of-concept data from Part A expected in 2H 2025; dose optimization Part B also planned.
- APG777 designed for less frequent dosing: 6 injections during induction vs 11 for lebrikizumab, 70-90% fewer in maintenance.
- Phase 2 asthma trial expected to initiate in 2025; pipeline-in-a-product strategy.

## SEC filing metadata
- accession: 0001104659-24-061998
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924061998/0001104659-24-061998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924061998/tm2414616d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061998
- JSON: https://secwatch.observer/filing/0001104659-24-061998.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.